The results of abnormal toxicity tests, antihypertensive substance inspections, allergic reaction tests and maximum dosage tests conducted in accordance with relevant standards and guidelines showed that this product had no abnormal toxic reactions, the antihypertensive substances met the requirements, there were no allergic reactions, and the maximum dosage was greater than 100ml/kg, which did not cause abnormal reactions or deaths in mice.

(1) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in the country, the product was injected into mice at a dose of 0.8 ml/mouse. No abnormal toxic reaction or death was observed within 48 hours after injection. The abnormal toxicity test results for mice were qualified. (2) According to the method requirements for the antihypertensive substance test in the appendix of the "Pharmacopoeia of the People's Republic of China", this product was tested for antihypertensive substances in cats, and the results met the antihypertensive substance requirements specified in the Pharmacopoeia. (3) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intraperitoneally into healthy white Hautley guinea pigs, 0.5 ml per guinea pig, once every other day, for 3 consecutive times for sensitization. The results showed that the product had no effect on the activity, food intake, and drinking water of guinea pigs, and had no significant effect on the weight gain of guinea pigs. No abnormal reactions occurred during the test, and no guinea pigs died. The incidence rate and mortality rate of allergic reactions were both 0.4) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intravenously into healthy clean-grade ICR mice at a dose of 100 ml/kg. After administration, no abnormal reactions were observed in male and female mice, and no animal deaths were caused. The maximum dosage for mice is greater than 100 ml/kg.

(1) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in the country, the product was injected into mice at a dose of 0.8 ml/mouse. No abnormal toxic reaction or death was observed within 48 hours after injection. The abnormal toxicity test results for mice were qualified. (2) According to the method requirements for the antihypertensive substance test in the appendix of the "Pharmacopoeia of the People's Republic of China", this product was tested for antihypertensive substances in cats, and the results met the antihypertensive substance requirements specified in the Pharmacopoeia. (3) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intraperitoneally into healthy white Hautley guinea pigs, 0.5 ml per guinea pig, once every other day, for 3 consecutive times for sensitization. The results showed that the product had no effect on the activity, food intake, and drinking water of guinea pigs, and had no significant effect on the weight gain of guinea pigs. No abnormal reactions occurred during the test, and no guinea pigs died. The incidence rate and mortality rate of allergic reactions were both 0.4) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intravenously into healthy clean-grade ICR mice at a dose of 100 ml/kg. After administration, no abnormal reactions were observed in male and female mice, and no animal deaths were caused. The maximum dosage for mice is greater than 100 ml/kg.

In accordance with the requirements of the "Non-clinical Research Management Standards for Drugs", tests were conducted on mice, guinea pigs and cats, and the results showed no abnormal toxic reactions, met the requirements for antihypertensive substances, and there were no allergic reactions or deaths.

(1) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in the country, the product was injected into mice at a dose of 0.8 ml/mouse. No abnormal toxic reaction or death was observed within 48 hours after injection. The abnormal toxicity test results for mice were qualified. (2) According to the method requirements for the antihypertensive substance test in the appendix of the "Pharmacopoeia of the People's Republic of China", this product was tested for antihypertensive substances in cats, and the results met the antihypertensive substance requirements specified in the Pharmacopoeia. (3) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intraperitoneally into healthy white Hautley guinea pigs, 0.5 ml per guinea pig, once every other day, for 3 consecutive times for sensitization. The results showed that the product had no effect on the activity, food intake, and drinking water of guinea pigs, and had no significant effect on the weight gain of guinea pigs. No abnormal reactions occurred during the test, and no guinea pigs died. The incidence rate and mortality rate of allergic reactions were both 0.4) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intravenously into healthy clean-grade ICR mice at a dose of 100 ml/kg. After administration, no abnormal reactions were observed in male and female mice, and no animal deaths were caused. The maximum dosage for mice is greater than 100 ml/kg.

(1) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in the country, the product was injected into mice at a dose of 0.8 ml/mouse. No abnormal toxic reaction or death was observed within 48 hours after injection. The abnormal toxicity test results for mice were qualified. (2) According to the method requirements for the antihypertensive substance test in the appendix of the "Pharmacopoeia of the People's Republic of China", this product was tested for antihypertensive substances in cats, and the results met the antihypertensive substance requirements specified in the Pharmacopoeia. (3) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intraperitoneally into healthy white Hautley guinea pigs, 0.5 ml per guinea pig, once every other day, for 3 consecutive times for sensitization. The results showed that the product had no effect on the activity, food intake, and drinking water of guinea pigs, and had no significant effect on the weight gain of guinea pigs. No abnormal reactions occurred during the test, and no guinea pigs died. The incidence rate and mortality rate of allergic reactions were both 0.4) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intravenously into healthy clean-grade ICR mice at a dose of 100 ml/kg. After administration, no abnormal reactions were observed in male and female mice, and no animal deaths were caused. The maximum dosage for mice is greater than 100 ml/kg.

In accordance with the requirements of the "Non-clinical Drug Research Management Standards" and the relevant national guidelines for preclinical research of new drugs, multiple tests on mice, guinea pigs and cats showed that this product had no abnormal toxic reactions, met the requirements of antihypertensive substances, no allergic reactions occurred, and the maximum dosage was greater than 100ml/kg, without causing animal death or abnormal reactions.

(1) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in the country, the product was injected into mice at a dose of 0.8 ml/mouse. No abnormal toxic reaction or death was observed within 48 hours after injection. The abnormal toxicity test results for mice were qualified. (2) According to the method requirements for the antihypertensive substance test in the appendix of the "Pharmacopoeia of the People's Republic of China", this product was tested for antihypertensive substances in cats, and the results met the antihypertensive substance requirements specified in the Pharmacopoeia. (3) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intraperitoneally into healthy white Hautley guinea pigs, 0.5 ml per guinea pig, once every other day, for 3 consecutive times for sensitization. The results showed that the product had no effect on the activity, food intake, and drinking water of guinea pigs, and had no significant effect on the weight gain of guinea pigs. No abnormal reactions occurred during the test, and no guinea pigs died. The incidence rate and mortality rate of allergic reactions were both 0.4) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intravenously into healthy clean-grade ICR mice at a dose of 100 ml/kg. After administration, no abnormal reactions were observed in male and female mice, and no animal deaths were caused. The maximum dosage for mice is greater than 100 ml/kg.

(1) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in the country, the product was injected into mice at a dose of 0.8 ml/mouse. No abnormal toxic reaction or death was observed within 48 hours after injection. The abnormal toxicity test results for mice were qualified. (2) According to the method requirements for the antihypertensive substance test in the appendix of the "Pharmacopoeia of the People's Republic of China", this product was tested for antihypertensive substances in cats, and the results met the antihypertensive substance requirements specified in the Pharmacopoeia. (3) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intraperitoneally into healthy white Hautley guinea pigs, 0.5 ml per guinea pig, once every other day, for 3 consecutive times for sensitization. The results showed that the product had no effect on the activity, food intake, and drinking water of guinea pigs, and had no significant effect on the weight gain of guinea pigs. No abnormal reactions occurred during the test, and no guinea pigs died. The incidence rate and mortality rate of allergic reactions were both 0.4) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intravenously into healthy clean-grade ICR mice at a dose of 100 ml/kg. After administration, no abnormal reactions were observed in male and female mice, and no animal deaths were caused. The maximum dosage for mice is greater than 100 ml/kg.

1. Effect on water and electrolyte excretion: It can increase the excretion of water, sodium, chloride, potassium, calcium, magnesium, phosphorus, etc. It mainly inhibits the active reabsorption of NaCl by the thick wall segment of the renal tubular loop, reduces the osmotic pressure gradient difference of the medullary interstitial fluid, and reduces the reabsorption of water, Na+, and Cl-; promotes the increase of Na+-K+ and Na+-H+ exchange in the distal tubule, increases the excretion of K+ and H+; inhibits the reabsorption of Ca2+ and Mg2+ by the loop of Henle and increases their excretion. Short-term medication can increase uric acid excretion, and long-term medication can cause hyperuricemia. 2. Effect on hemodynamics: Furosemide can inhibit the activity of prostaglandin degrading enzymes, increase the content of prostaglandin E2, dilate blood vessels, reduce renal vascular resistance, and increase renal blood flow; dilate pulmonary capacitance veins, reduce pulmonary capillary permeability, reduce ventricle return blood volume, and reduce left ventricular end-diastolic pressure, which is helpful for the treatment of acute left heart failure and provides a theoretical basis for the treatment of adult respiratory distress syndrome.

It participates in amino acid metabolism, synthesis of neurotransmitters, synthesis of collagen and tissue cell interstitial, can reduce the permeability of capillaries, accelerate blood coagulation, stimulate coagulation function, promote iron absorption in the intestine, promote the decrease of blood lipids, increase resistance to infection, participate in detoxification function, and has antihistamine effect and prevents the formation of carcinogens (nitrosamines).